Vanda Pharmaceuticals Inc. (VNDA) is a global biopharmaceutical company focused on the development and commercialization of innovative therapies to address high unmet medical needs and improve the lives of patients. Founded in 2002 and headquartered in Washington D.C., the company is dedicated to the advancement of a diverse portfolio of products and product candidates, including both proprietary compounds and co-developed strategic partnerships.
One of Vanda's primary goals is to develop and commercialize products that can treat disorders of the central nervous system, where the potential health impact is significant and the demand for better treatment options is high. The range of disorders includes schizophrenia, jet lag disorder, and various sleep disorders among others.
Vanda Pharmaceuticals has two products in the market: Fanapt (iloperidone) and Hetlioz (tasimelteon). Fanapt is an atypical antipsychotic approved by the FDA for the treatment of schizophrenia in adults, while Hetlioz is used to treat sleep and wake disorders. Both of these FDA-approved products highlight Vanda's commitment to robust scientific discovery and the pursuit of novel treatments.
Vanda's business strategy is based around the identification, development, and commercialization of late-stage product candidates. One of the remarkable characteristics of Vanda's pipeline is the advanced state of their clinical programs. The company invests highly in research and development to ensure its position at the forefront of innovative healthcare solutions.
Despite its primary focus on central nervous system disorders, Vanda is also dedicated to developing treatments for other health problems. This include bacterial infections, ocular diseases, and oncology. The company is involved in multiple partnerships with leading pharmaceutical companies to co-develop these treatments, facilitating the broad distribution of their products globally.
From a financial perspective, Vanda Pharmaceuticals is a publicly-traded company listed on the NASDAQ stock exchange under ticker symbol 'VNDA'. It has garnered the attention and backing of several prominent investors and institutions due to its pioneering work in the biopharmaceutical space.
Vanda Pharmaceuticals is committed to the patients it serves and aims to enrich their lives by providing effective therapeutic solutions. The company's vision is to become a global leader in the biopharmaceutical industry by continuously pushing the boundaries of medical innovation. It stands as an ongoing testament to the role innovation and dedication can play in improving healthcare outcomes worldwide.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
Vanda Pharmaceuticals announced positive Phase III results for NEREUS (tradipitant) in preventing vomiting associated with GLP-1 receptor agonist therapy, showing a 27% relative reduction in vomiting incidence. The study also demonstrated significant reductions in severe nausea, frequent multi-day vomiting, and extreme vomiting, with NEREUS being generally well tolerated. Vanda plans to submit a supplemental New Drug Application to the FDA, hoping to expand NEREUS's use to improve GLP-1 treatment adherence.
Vanda Pharmaceuticals (NASDAQ: VNDA) reported a 24% year-over-year revenue growth in Q3 2026, primarily driven by Fanapt and the new launch of Nyrius, with operating expenses decreasing by 18% from the previous quarter. The company anticipates the commercial launch of Bisanti in Q4 2026 and has a pending BLA for Quimilza with an FDA decision expected in December, while also pursuing regulatory approvals for Nyrius in GLP-1–induced vomiting and Hetlioz for delayed sleep-wake phase disorder. Vanda Pharma ended the quarter with $140.5 million in cash, emphasizing continued strong momentum for Fanapt and strategic efforts to expand its product portfolio and reduce operating expenses for long-term profitability.
Vanda Pharmaceuticals Inc. announced positive results from its Phase 3 trial for Nereus, an oral therapy designed to prevent vomiting caused by GLP-1 receptor agonist treatments. The company plans to submit a supplemental New Drug Application to the FDA, aiming to expand Nereus's label to address a critical tolerability issue in the GLP-1 market. The trial demonstrated significant reductions in vomiting incidence and severity, particularly when Nereus was administered preventatively.
Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) announced that its experimental anxiety treatment, VQW-765, failed to meet its primary and secondary endpoints in a Phase 3 trial. The drug, intended for acute social anxiety, showed no significant benefit over a placebo in adult participants. This outcome contradicts promising data from an earlier Phase 2 study, leading to a drop in Vanda Pharmaceuticals' stock.